Dare Bioscience (DARE) Net Income towards Common Stockholders (2013 - 2026)

Dare Bioscience (DARE) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$1.6 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 69.4% year-over-year to -$1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$20.4 million (up 15.04% YoY) and the FY2025 annual result came in at -$13.4 million, down 230.55% from the prior year.
• Net Income towards Common Stockholders grew to -$1.6 million in Q4 2025, from -$5.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $304322.0 in Q2 2022 to a low of -$15.9 million in Q4 2022.
• A 5-year average of -$7.4 million and a median of -$7.7 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 103.28% — and 2023, when it slumped 3088.4%.
• Tracing DARE's Net Income towards Common Stockholders over 5 years: stood at -$9.5 million in 2021, then sank by 67.08% to -$15.9 million in 2022, then soared by 45.04% to -$8.8 million in 2023, then soared by 38.95% to -$5.3 million in 2024, then soared by 69.4% to -$1.6 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$1.6 million (Q4 2025), -$5.8 million (Q3 2025), and -$5.9 million (Q2 2025), per Business Quant data.